In this context, our rat PVL model provides translational insight into how hepatic hypertrophy may modulate tumor behavior under EGFR inhibition, helping to interpret why perioperative cetuximab could yield unexpected oncological outcomes in clinical practice. This evidence concerns the gene EGFR and neoplasm.